Fine chemical

DGAP-News: Gerresheimer AG: Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India

Retrieved on: 
Monday, May 16, 2022 - 9:04am

Gerresheimer has significantly ramped up its glass and plastic production capacities in India to satisfy its global pharma customer needs.

Key Points: 
  • Gerresheimer has significantly ramped up its glass and plastic production capacities in India to satisfy its global pharma customer needs.
  • By adding capacities in India, Gerresheimer executes on its growth strategy in Emerging Markets addressing the global mega trend for increasing health care access in these markets and the rising demand for vaccination.
  • India is one of the strongest growing country within the Emerging Markets and a core market of large global pharma companies, CEO Dietmar Siemssen said.
  • The capacity increase in India is part of Gerresheimers investment program to sharpen the companys growth and return profile.

Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia

Retrieved on: 
Monday, May 16, 2022 - 8:11am

Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.

Key Points: 
  • Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.
  • Naveed Siddiqi, Senior Partner at Novo Holdings, serves as a Board Member of F2G and Eric Snyder, Partner at Novo Holdings, as Board Observer.
  • Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections.
  • Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.

Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia

Retrieved on: 
Monday, May 16, 2022 - 8:09am

Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.

Key Points: 
  • Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.
  • Naveed Siddiqi, Senior Partner at Novo Holdings, serves as a Board Member of F2G and Eric Snyder, Partner at Novo Holdings, as Board Observer.
  • Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections.
  • Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.

A breakthrough in biopharmaceutical protein production; LenioBio announces a new proprietary cell line devoid of plant glycans

Retrieved on: 
Monday, May 16, 2022 - 8:00am

LenioBio's proprietary ALiCE platform is derived from a tobacco BY-2 plant cell lysate.

Key Points: 
  • LenioBio's proprietary ALiCE platform is derived from a tobacco BY-2 plant cell lysate.
  • Plant-based expression systems are ideal biofactories for the production of many different protein classes for a multitude of applications.
  • In a step towards offering greater flexibility to their customers, LenioBio has generated a BY-2 knockout cell line lacking those enzymes responsible for plant-specific fucose and xylose glycosylation.
  • The resulting lysate devoid of plant glycans, opens the door to a new line of ALiCE products offering the potential for customizable protein glycosylation.

A breakthrough in biopharmaceutical protein production; LenioBio announces a new proprietary cell line devoid of plant glycans

Retrieved on: 
Monday, May 16, 2022 - 8:00am

LenioBio's proprietary ALiCE platform is derived from a tobacco BY-2 plant cell lysate.

Key Points: 
  • LenioBio's proprietary ALiCE platform is derived from a tobacco BY-2 plant cell lysate.
  • Plant-based expression systems are ideal biofactories for the production of many different protein classes for a multitude of applications.
  • However, differences in the way plant cells and the cells of other organisms perform the important post-translational protein glycosylation step can limit the uses of some plant CFPS-produced proteins.
  • The resulting lysate devoid of plant glycans, opens the door to a new line of ALiCE products offering the potential for customizable protein glycosylation.

Nicox Announces a New Governance Structure

Retrieved on: 
Monday, May 16, 2022 - 6:30am

Michele Garufi will remain as Board member of Nicox SA.

Key Points: 
  • Michele Garufi will remain as Board member of Nicox SA.
  • Jean-Franois Labb has served as a member of Nicox Board of Directors since 2010 and has been the Chairman of the Audit Committee of Nicox since 2013.
  • Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health.
  • Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Axion BioSystems Welcomes Biotech Industry Leader Kevin Gould as New CEO

Retrieved on: 
Monday, May 16, 2022 - 5:00am

Axion BioSystems, a leading life science tools company focused on advanced live-cell assay platforms , announces that Kevin Gould has been appointed the companys Chief Executive Officer, effective immediately.

Key Points: 
  • Axion BioSystems, a leading life science tools company focused on advanced live-cell assay platforms , announces that Kevin Gould has been appointed the companys Chief Executive Officer, effective immediately.
  • View the full release here: https://www.businesswire.com/news/home/20220515005001/en/
    Kevin takes over today from Axions long-time CEO Tom OBrien, who will be retiring July 15th.
  • OBrien, who co-founded Axion BioSystems in 2008 with Chief Technical Officer Jim Ross, said that Gould is a natural fit for leading the company.
  • Kevins experience in the industry speaks for itself and his passion for driving biotech research forward is unparalleled.

Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.

Retrieved on: 
Sunday, May 15, 2022 - 10:00pm

KemPharm is a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system diseases.

Key Points: 
  • KemPharm is a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system diseases.
  • KemPharm will pay Orphazyme a total of USD 12.8 million in cash and assume liabilities estimated to equal approximately USD 5.2 million.
  • Since Orphazyme is under in-court restructuring, the primary objective was to secure a deal that satisfies our obligations towards the creditors including our employees.
  • Following completion of the deal, Orphazyme will no longer have any ongoing operational business activities.

DGAP-News: Results for the year ended 31 December 2021

Retrieved on: 
Saturday, May 14, 2022 - 12:02am

Sales in USA corn were up 133% in 2021, driven by strong demand for the Group's Harpin seed treatment product.

Key Points: 
  • Sales in USA corn were up 133% in 2021, driven by strong demand for the Group's Harpin seed treatment product.
  • Sales of Harpin for PHC in Brazil sugarcane grew 108% even under challenging drought conditions in 2021.
  • Sugar cane growers experienced extreme drought during the 2021 growing season which reduced yield by more than 13%.
  • 2021 sales in the EMEAA region were up 31% with growth in Spain and the UK.